Argenx Se (ARGX) Revenue (2016 - 2026)
Argenx Se (ARGX) posted Revenue of $1.3 billion for Q1 2026, up 0.96% on a QoQ basis from $1.3 billion in Q4 2025, and up 64.3% year-over-year from $790.0 million in Q1 2025.
Argenx Se (ARGX) Revenue (2016 - 2026) Analysis & Trends
Argenx Se's Revenue history runs 11 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- Quarterly Revenue rose 64.3% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 billion (up 80.76% YoY) and the FY2025 annual result came in at $4.2 billion, up 89.91% from the prior year.
- Revenue was $1.3 billion for Q1 2026 at Argenx Se, up from $1.3 billion in the prior quarter.
- Across five years, Revenue topped out at $1.3 billion in Q1 2026 and bottomed at $21.2 million in Q1 2022.
- A 5-year average of $542.7 million and a median of $398.3 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue plunged 99.98% — and 2023, when it surged 930.2%.
- Argenx Se's Revenue stood at $173.4 million in 2022, then surged by 115.89% to $374.4 million in 2023, then jumped by 96.87% to $737.0 million in 2024, then surged by 74.46% to $1.3 billion in 2025, then gained by 0.96% to $1.3 billion in 2026.
- Business Quant data shows ARGX's Revenue at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Bn |
| Dec 31, 2025 | 1.29 Bn |
| Sep 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 948.59 Mn |
| Mar 31, 2025 | 790.00 Mn |
| Dec 31, 2024 | 736.97 Mn |
| Sep 30, 2024 | 573.00 Mn |
| Jun 30, 2024 | 477.64 Mn |
| Mar 31, 2024 | 398.28 Mn |
| Dec 31, 2023 | 374.35 Mn |
| Sep 30, 2023 | 329.10 Mn |
| Jun 30, 2023 | 269.31 Mn |
| Mar 31, 2023 | 218.02 Mn |
| Dec 31, 2022 | 173.40 Mn |
| Sep 30, 2022 | 131.33 Mn |
| Jun 30, 2022 | 74.83 Mn |
| Mar 31, 2022 | 21.16 Mn |
| Dec 31, 2021 | 26.02 Mn |
| Sep 30, 2021 | 857.00 Bn |
| Jun 30, 2021 | -63.03 Mn |